Market Access and Reimbursement Q&A with AviadoBio CEO Lisa Deschamps
SHARE NOW
Lisa Deschamps, AviadoBio CEO and former SVP and CBO at Novartis joined us to discuss the recent Orphan Drug designation received by AviadoBio’s gene therapy targeting frontotemporal dementia from both the FDA and EC, and, the issues surrounding market access and reimbursement of such therapies.
The Orphan Drug designation granted to AviadoBio’s AVB-101 AAV gene therapy for frontotemporal dementia, in both Europe and the U.S., covered recently by Phacilitate, opens an pathway of support and acceleration by the regulatory bodies. The nature of innovative cell and gene therapies often means they come up against challenges in the traditional models of regulation and beyond approval at the reimbursement stages.
What are the challenges faced by advanced therapies to market access and reimbursement, and, how can they be overcome so that patients can access the transformative potentials of these therapies? Lisa shares her experiences, expertise and insights.
Lisa will be speaking about Market Access and Reimbursement at Phacilitate’s Advanced Therapies Europe 2022, taking place between the 31st of August and 1st of September at the Royal Lancaster London.
Find out more about and register your place at Phacilitate’s Advanced Therapies Europe 2022 here >>
